To maximize Series A runway, biotech investors must look for this key trait
To get to Series B, biotechs must kill dead-end projects fast: prior success + failure predict which shave years of waste
The trick for using “green bonds” to access institutional equity
Issuing green bonds for sustainability projects can increase stock price and ownership amongst key institutional investors
A little customer focus goes a long way for a biotech being acquired
Early-stage biotechs that put extra effort into customer focus are rewarded with a higher likelihood of being acquired by big pharma
Unlocking hidden value - easy trick for managing creative startups post-acquisition
Big Value in Big Data? Here's how to signal the market about it
